DNA-protein cross-links are formed by various DNA-damaging agents including antitumor platinum drugs. The natures of these ternary DNA-Pt-protein complexes (DPCLs) can be inferred, yet much remains to be learned about their structures and mechanisms of formation. We investigated the origin of these DPCLs and their cellular processing on molecular level using gel electrophoresis shift assay. We show that in cell-free media cisplatin [cis-diamminedichloridoplatinum(II)] forms DPCLs more effectively than ineffective transplatin [trans-diamminedichloridoplatinum(II)]. Mechanisms of transformation of individual types of plain DNA adducts of the platinum complexes into the DPCLs in the presence of several DNA-binding proteins have been also investigated. The DPCLs are formed by the transformation of DNA monofunctional and intrastrand cross-links of cisplatin. In contrast, interstrand cross-links of cisplatin and monofunctional adducts of transplatin are stable in presence of the proteins. The DPCLs formed by cisplatin inhibit DNA polymerization or removal of these ternary lesions from DNA by nucleotide excision repair system more effectively than plain DNA intrastrand or monofunctional adducts. Thus, the bulky DNA-protein cross-links formed by cisplatin represent a more distinct and persisting structural motif recognized by the components of downstream cellular systems processing DNA damage considerably differently than the plain DNA adducts of this metallodrug.

Institute of Biophysics Academy of Sciences of the Czech Republic Brno Czech Republic

Zobrazit více v PubMed

Johnson NP, Butour JL, Villani G, Wimmer FL, Defais M, Pierson V, Brabec V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 1989;10:1–24.

Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 2002;71:1–68. PubMed

Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 1987;34:155–166. PubMed

Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 2001;67:93–130. PubMed

Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 2003;103:645–662. PubMed

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery. 2005;4:307–320. PubMed

Wozniak K, Walter Z. Induction of DNA-protein cross-links by platinum compounds. Z. Naturforsch. C. 2000;55:731–736. PubMed

Zwelling LA, Anderson T, Kohn KW. DNA - protein and DNA interstrand cross-linking by cis- and trans-platinum(II)diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979;39:365–369. PubMed

Olinski R, Wedrychovski A, Schmidt WN, Briggs RC, Hnilica LS. In vivo DNA-protein cross-linking by cis- and trans-diamminedichloroplatinum(II) Cancer Res. 1987;47:201–205. PubMed

Yamamoto J, Miyagi Y, Kawanishi K, Yamada S, Kodama J, Yoshinouchi M, Kudo T. Effect of cisplatin on cell death and DNA crosslinking in rat mammary adenocarcinoma in vitro. Acta Med. Okayama. 1999;53:201–208. PubMed

Farrell N, Povirk LF, Dange Y, DeMasters G, Gupta MS, Kohlhagenc G, Khanc QA, Pommier Y, Gewirtz DA. Cytotoxicity, DNA strand breakage and DNA–protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem. Pharmacol. 2004;68:857–866. PubMed

Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999;99:2467–2498. PubMed

Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001;478:1–21. PubMed

Wozniak K, Walter Z. Immunospecific protein of 34.5 kDa from DNA-protein cross-links induced by cis- and trans-diamminedichloroplatinum. Cell Biol. Int. 2002;26:495–503. PubMed

Novakova O, Kasparkova J, Malina J, Natile G, Brabec V. DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res. 2003;31:6450–6460. PubMed PMC

Brabec V, Kleinwächter V, Butour JL, Johnson NP. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem. 1990;35:129–141. PubMed

Kasparkova J, Novakova O, Marini V, Najajreh Y, Gibson D, Perez J-M, Brabec V. Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: mechanistic studies on antitumor action. J. Biol. Chem. 2003;278:47516–47525. PubMed

Malina J, Kasparkova J, Natile G, Brabec V. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts. Chem. Biol. 2002;9:629–638. PubMed

Manley JL, Fire A, Cano A, Sharp PA, Gefter ML. DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract. Proc. Natl. Acad. Sci. U.S.A. 1980;77:3855–3859. PubMed PMC

Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 1999;59:3968–3971. PubMed

Yaneva J, Leuba SH, van Holde K, Zlatanova J. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. Proc. Natl. Acad. Sci. U.S.A. 1997;94:13448–13451. PubMed PMC

Hoffmann JS, Johnson NP, Villani G. Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum(II) to bifunctional lesions. Effect on the in vitro replication of single-stranded DNA by Escherichia coli DNA polymerase I and eukaryotic DNA polymerases alpha. J. Biol. Chem. 1989;264:15130–15135. PubMed

Vrana O, Kiseleva VI, Poverenny AM, Brabec V. Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II) - immunochemical analysis. Eur. J. Pharmacol. 1992;226:5–13. PubMed

Bancroft DP, Lepre CA, Lippard SJ. Pt-195 NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc. 1990;112:6860–6871.

Eastman A, Barry MA. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry. 1987;26:3303–3307. PubMed

Bernal-Mendez E, Boudvillain M, Gonzalez-Vilchez F, Leng M. Chemical versatility of transplatin monofunctional adducts within multiple site-specifically platinated DNA. Biochemistry. 1997;36:7281–7287. PubMed

Comess KM, Burstyn JN, Essigmann JM, Lippard SJ. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis- diamminedichloroplatinum(II) DNA adducts. Biochemistry. 1992;31:3975–3990. PubMed

Suo Z, Johnson K. DNA secondary structure effects on DNA synthesis catalyzed by HIV-1 reverse transcriptase. J. Biol. Chem. 1998;273:27259–27267. PubMed

Suo Z, Lippard S, Johnson K. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry. 1999;38:715–726. PubMed

Sancar A. DNA excision repair. Annu. Rev. Biochem. 1996;65:43–81. PubMed

Reardon JT, Sancar A. Molecular mechanism of nucleotide excision repair in mammalian cells. In: Dizdaroglu M, Karakaya A, editors. Advances in DNA Damage and Repair. New York: Plenum Publishing Corp.; 1998. pp. 377–393.

Marini V, Christofis P, Novakova O, Kasparkova J, Farrell N, Brabec V. Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)] Nucleic Acids Res. 2005;33:5819–5828. PubMed PMC

Plooy ACM, Van Dijk M, Lohman PHM. Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984;44:2043–2051. PubMed

Olinski R, Briggs RC. DNA-protein cross-linking in L1210 cells and resistant to cis-diamminedichloroplatinum(II) Mol. Biol. Rep. 1991;15:81–86. PubMed

Huang HF, Zhu LM, Reid BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 1995;270:1842–1845. PubMed

Coste F, Malinge JM, Serre L, Shepard W, Roth M, Leng M, Zelwer C. Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site. Nucleic Acids Res. 1999;27:1837–1846. PubMed PMC

Lemaire MA, Schwartz A, Rahmouni AR, Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. U.S.A. 1991;88:1982–1985. PubMed PMC

Natile G, Coluccia M. Current status of trans-platinum compounds in cancer therapy. Coord. Chem. Rev. 2001;216:383–410.

Costa M. DNA-protein complexes induced by chromate and other carcinogens. Environ. Health Persp. 1991;92:45–52. PubMed PMC

Reardon JT, Sancar A. Repair of DNA-polypeptide crosslinks by human excision nuclease. Proc. Natl. Acad. Sci. U.S.A. 2006;103:4056–4061. PubMed PMC

Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II) Cancer Res. 1987;47:3000–3004. PubMed

Travers A. Mapping histone positions in chromatin by protein = directed DNA crosslinking and cleavage. In: Travers A, Buckle M, editors. DNA-Protein Interactions. Oxford, New York: Oxford University Press; 2000. pp. 229–238.

Kloster M, Kostrhunova H, Zaludova R, Malina J, Kasparkova J, Brabec V, Farrell N. Trifunctional dinuclear platinum complexes as DNA-protein cross-linking agents. Biochemistry. 2004;43:7776–7786. PubMed

Walking of antitumor bifunctional trinuclear PtII complex on double-helical DNA

DNA adducts of antitumor cisplatin preclude telomeric sequences from forming G quadruplexes